Summary:
Investing in developing a durable platform and strategy early leads to fewer delays throughout development. Locking requirements in early and educating teams to approach combination product development holistically lowers the time to development dramatically. In this panel discussion from the 2025 PODD: Partnership Opportunities in Drug Delivery Conference, pharma executives and drug delivery experts discuss how they used platform devices in concert with an internal engagement strategy to speed up development. Specifically, they address:
- Advantages and disadvantages to platform approaches for device development
- Opportunities to overcome technical limitations
- Approaches to bring a platform into multiple product design history files
- Regulatory hurdles
- Assessing business case and getting organizational buy-in
To learn more about the PODD Conference, please visit Drug-Delivery.org.
Moderators
Lindsey Crawford, PhD
Senior Principal Scientist
Pfizer
Panelists
Monica Swinney, PhD
Senior Director, New Product Planning & Drug Delivery Innovation
Gilead Sciences
Tim Quigg
Development Director
Crux Product Design
Shirish Ingawale, PhD
Director, Device and Combination Product Development
Takeda
Bradley Gould, MEng
Director, Device and Combination Product Development
AbbVie
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.